Hector Tamez

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/10565900/hector-tamez-publications-by-year.pdf

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

46
papers

4,310
citations

47
papers

4,862
ext. papers

4,862
avg, IF

47
L-index

#	Paper	IF	Citations
46	Predicting Residual Angina After Chronic Total Occlusion Percutaneous Coronary Intervention: Insights from the OPEN-CTO Registry <i>Journal of the American Heart Association</i> , 2022 , 11, e024056	6	1
45	Estimation of DAPT Study Treatment Effects in Contemporary Clinical Practice: Findings from the EXTEND-DAPT Study. <i>Circulation</i> , 2021 ,	16.7	4
44	Impact of adherence to the hybrid algorithm for initial crossing strategy selection in chronic total occlusion percutaneous coronary intervention. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2021 , 74, 1023-1031	0.7	
43	Comparability of Event Adjudication Versus Administrative Billing Claims for Outcome Ascertainment in the DAPT Study: Findings From the EXTEND-DAPT Study. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021 , 14, e006589	5.8	6
42	Long-term outcomes of percutaneous coronary intervention for in-stent restenosis among Medicare beneficiaries. <i>EuroIntervention</i> , 2021 , 17, e380-e387	3.1	4
41	Use of Administrative Claims to Assess Outcomes and Treatment Effect in Randomized Clinical Trials for Transcatheter Aortic Valve Replacement: Findings From the EXTEND Study. <i>Circulation</i> , 2020 , 142, 203-213	16.7	8
40	Retrograde Chronic Total Occlusion Percutaneous Coronary Intervention via Saphenous Vein Graft. <i>JACC: Cardiovascular Interventions</i> , 2020 , 13, 517-526	5	12
39	The Impact of Peripheral Artery Disease in Chronic Total Occlusion Percutaneous Coronary Intervention (Insights From PROGRESS-CTO Registry). <i>Angiology</i> , 2020 , 71, 274-280	2.1	5
38	Use of Administrative Claims Data to Estimate Treatment Effects for 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: Findings From the EXTEND-DAPT Study. <i>Circulation</i> , 2020 , 142, 306-308	16.7	3
37	Validating the use of registries and claims data to support randomized trials: Rationale and design of the Extending Trial-Based Evaluations of Medical Therapies Using Novel Sources of Data (EXTEND) Study. <i>American Heart Journal</i> , 2019 , 212, 64-71	4.9	14
36	Depression and Angina Among Patients Undergoing Chronic Total Occlusion Percutaneous Coronary Intervention: The OPEN-CTO Registry. <i>JACC: Cardiovascular Interventions</i> , 2019 , 12, 651-658	5	11
35	Comparison of Clinical Trials and Administrative Claims to Identify Stroke Among Patients Undergoing Aortic Valve Replacement: Findings From the EXTEND Study. <i>Circulation: Cardiovascular Interventions</i> , 2019 , 12, e008231	6	12
34	Contemporary Use and Trends in Unprotected Left Main Coronary Artery Percutaneous Coronary Intervention in the United States: An Analysis of the National Cardiovascular Data Registry Research to Practice Initiative. <i>JAMA Cardiology</i> , 2019 , 4, 100-109	16.2	27
33	Association of Physician Variation in Use of Manual Aspiration Thrombectomy With Outcomes Following Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction: The National Cardiovascular Data Registry CathPCI Registry. <i>JAMA Cardiology</i> , 2019 , 4, 110-118	16.2	15
32	Effect of Short Procedural Duration With Bivalirudin on Increased Risk of Acute Stent Thrombosis in Patients With STEMI: A Secondary Analysis of the HORIZONS-AMI Randomized Clinical Trial. JAMA Cardiology, 2017 , 2, 673-677	16.2	4
31	Type 4a myocardial infarction: Incidence, risk factors, and long-term outcomes. <i>Catheterization and Cardiovascular Interventions</i> , 2017 , 89, 849-856	2.7	11
30	Serum phospholipid fraction of polyunsaturated fatty acids is the preferred indicator for nutrition and health status in hemodialysis patients. <i>Journal of Nutritional Biochemistry</i> , 2016 , 38, 18-24	6.3	1

(2012-2016)

29	African Americans with left ventricular hypertrophy and chronic kidney disease: what should we do?. <i>Nephrology Dialysis Transplantation</i> , 2016 , 31, 1969-1970	4.3	
28	Removal of Soluble Fms-Like Tyrosine Kinase-1 by Dextran Sulfate Apheresis in Preeclampsia. Journal of the American Society of Nephrology: JASN, 2016 , 27, 903-13	12.7	164
27	Nutritional vitamin D supplementation in dialysis: a randomized trial. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015 , 10, 611-9	6.9	52
26	Prognosis of Acute Kidney Injury and Hepatorenal Syndrome in Patients with Cirrhosis: A Prospective Cohort Study. <i>International Journal of Nephrology</i> , 2015 , 2015, 108139	1.7	38
25	Vitamin D and Its Effects on the Heart 2015 , 107-116		
24	Vitamin D and chronic kidney disease-mineral bone disease (CKD-MBD). <i>BoneKEy Reports</i> , 2014 , 3, 498		42
23	Vitamin D-binding protein and vitamin D status of black Americans and white Americans. <i>New England Journal of Medicine</i> , 2013 , 369, 1991-2000	59.2	758
22	Reply to "The role of fibroblast growth factor-23 in left atrial volume". <i>American Heart Journal</i> , 2013 , 165, e23	4.9	1
21	Inverse relationship between long-chain n-3 fatty acids and risk of sudden cardiac death in patients starting hemodialysis. <i>Kidney International</i> , 2013 , 83, 1130-5	9.9	40
20	Impact of new vitamin D data on future studies and treatment. <i>Current Opinion in Nephrology and Hypertension</i> , 2013 , 22, 377-82	3.5	5
19	Does vitamin D modulate blood pressure?. <i>Current Opinion in Nephrology and Hypertension</i> , 2013 , 22, 204-9	3.5	44
18	Carbamylation of serum albumin and erythropoietin resistance in end stage kidney disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013 , 8, 1927-34	6.9	27
17	Active vitamin D treatment for reduction of residual proteinuria: a systematic review. <i>Journal of the American Society of Nephrology: JASN</i> , 2013 , 24, 1863-71	12.7	113
16	Fatty acids and other risk factors for sudden cardiac death in patients starting hemodialysis. <i>American Journal of Nephrology</i> , 2013 , 38, 12-8	4.6	20
15	Phospholipid PUFA: a better indicator for assessing health risks. FASEB Journal, 2013, 27, 1072.16	0.9	
14	Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease. <i>American Heart Journal</i> , 2012 , 164, 902-9.e2	4.9	95
13	Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , 2012 , 307, 674-	8 2 7·4	406
12	Vitamin D and hypertension: an update and review. <i>Current Opinion in Nephrology and Hypertension</i> , 2012 , 21, 492-9	3.5	32

11	Low blood levels of long-chain n-3 polyunsaturated fatty acids in US hemodialysis patients: clinical implications. <i>American Journal of Nephrology</i> , 2012 , 36, 451-8	4.6	28
10	Soluble erythropoietin receptor contributes to erythropoietin resistance in end-stage renal disease. <i>PLoS ONE</i> , 2010 , 5, e9246	3.7	37
9	Role of Vitamin D and Vitamin D Analogs for Bone Health and Survival in Chronic Kidney Disease 2010 , 955-965		
8	Low plasma level of cathelicidin antimicrobial peptide (hCAP18) predicts increased infectious disease mortality in patients undergoing hemodialysis. <i>Clinical Infectious Diseases</i> , 2009 , 48, 418-24	11.6	115
7	Plasma gelsolin and circulating actin correlate with hemodialysis mortality. <i>Journal of the American Society of Nephrology: JASN</i> , 2009 , 20, 1140-8	12.7	71
6	Phosphorus binders and survival on hemodialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2009 , 20, 388-96	12.7	299
5	Reply to DiNubile. <i>Clinical Infectious Diseases</i> , 2009 , 49, 164-165	11.6	
4	Klotho variants and chronic hemodialysis mortality. <i>Journal of Bone and Mineral Research</i> , 2009 , 24, 184	7655	45
3	Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. <i>New England Journal of Medicine</i> , 2008 , 359, 584-92	59.2	1320
2	Impact of activated vitamin D and race on survival among hemodialysis patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2008 , 19, 1379-88	12.7	145
1	Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007 , 104, 16810-5	11.5	274